^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy

Published date:
03/27/2021
Excerpt:
Targeted biopsies were obtained from 37 men with intermediate- to high-risk prostate cancer before receiving 6 mo of ADT plus enzalutamide...Loss of chromosome 10q (containing PTEN) and alterations to TP53 were predictive of poor response…
DOI:
10.1016/j.eururo.2021.03.009